AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2023
Dec 5, 2023
30604_dirs_2023-12-05_5425eee8-cf94-4c87-be1e-2f33c8e85446.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-12-01
Reporting Person: Scott Randal W. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-12-01 | Common Stock | S | 1000 | $28.50 | Disposed | 12500 | Indirect |
| 2023-12-01 | Common Stock | S | 1500 | $30.00 | Disposed | 11000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5000 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
F2: By Thinking Bench Capital LLC.
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3